Association of interferon-γ, interleukin-10, and tumor necrosis factor-α gene polymorphisms with occurrence and severity of Eales' disease

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 171-178

  Sen, Aditi ^a   Paine, Suman Kalyan ^a   Chowdhury, Imran Hussain ^a   Mondal, Lakshmi Kanta ^b   Mukherjee, Amrita ^a   Biswas, Atanu ^b   Chowdhury, Subhankar ^c   Bhattacharya, Sujata ^d   Bhattacharya, Basudev ^a  

^a Dr BC Roy Post Graduate Institute of Basic Medical Sciences   (India)

^b Regional Institute of Ophthalmology   (India)

^c Endocrinology and Metabolism   (India)

^d R G KAR MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GENOMIC DNA; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN;

ADULT; AMPLIFICATION REFRACTORY MUTATION SYSTEM POLYMERASE CHAIN REACTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EALES DISEASE; FEMALE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HAPLOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; CLASSIFICATION; ETHNOLOGY; GENETICS; HOSPITALIZATION; NEOVASCULARIZATION (PATHOLOGY); RETINA VASCULITIS;

ADULT; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMANS; INDIA; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETINAL VASCULITIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952206870     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5885     Document Type: Article

References (49)

1. Eales H. Primary retinal hemorrhage in young men. Ophthalmic Rev. 1882;1:41.
2. Elliot AJ. 30-year observation of patient with Eales' disease. Am J Ophthalmol. 1975;80:404-408.
3. Das T, Biswas J, Kumar A, et al. Eales' disease. Indian J Ophthal-mol. 1994;42:3-28.
4. Biswas J, Sharma T, Gopal L Madhavan HN, Sulochana KN, Ra-makrishnan S. Eales' disease: an update. Surv Ophthalmol. 2002; 47(3):197-214.
5. Abu El-Asrar AM, Al-Kharashi SA. Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales' disease). Br J Ophthalmol. 2002;86:1248-1251.
6. Biswas J, Jain M, Narain S, Roy S, Madhavan HN. Evaluation of lymphocytes proliferation assay to purified protein derivative, enzyme linked immunosorbent assay and tuberculin hypersensitivity in Eales' disease. Indian J Ophthalmol. 1997;45:93-97.
7. Madhavan HN, Therese KL, Gunisha P, Jayanthi U, Biswas J. Polymerase chain reaction for detection of Mycobacterium tuberculosis in epiretinal membranes in Eales' disease. Invest Ophthalmol Vis Sci. 2000 41(3):822-825.
8. Therese KL, Deepa P, Therese J, Bagyalakshmi R, Biswas J, Madhavan HN. Association of mycobacteria with Eales' disease. Indian J Med Res. 2007;126(1):56-62.
9. Biswas J, Mukesh BN, Naratin S et al. Profiling of human leukocyte antigens in Eales' disease. Int Ophthalmol. 1998;21:277-281.
10. Billiau A. Interferon y: biology and role in pathogenesis. Adv Immunol. 1996;62:61-130.
11. Goldsby RA, Kindt TJ, Osborne BA. Leukocyte migration and inflammation. Kuby Immunol. 2001;4:388-391
12. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature. 1987;329:630-632.
13. Saren P, Welgus H, Kovanen P. TNF-α and IL-1/3 selectively induce expression of 92kDa gelatinase by human macrophages. J Immunol. 1996;57:4159-4165.
14. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor a-dependent angiogenesis. Mol Cell Biol. 1997;17:4015-4023.
15. Atmaca LS, Idil A, Gunduz K. Visualization of retinal vasculitis in Eales' disease. OculImmunolInflammol. 1993;1:41-48.
16. Moore KW, de Waal Malefyt R, Coffman RL. O'Garra A. Interleu-kin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001; 19:683-765.
17. Inoue G. Effect of interleukin-10 (IL10) on experimental LPS-induced acute lung injury.JInfect Chemother. 2000;6:51-60.
18. Huang S, Ullrich SE, Bar-Eli M. Regulation of tumour growth and metastasis by interleukin 10: the melanoma experience. J Interferon Cytokine Res. 1999;19:697-703
19. Saxena S, Pant AB, Khanna VK, et al. Interleukin-1 and tumor necrosis factor-alpha: novel targets for immunotherapy in Eales disease. Ocul Immunol Inflamm. 2009;17(3):201-206.
20. Bidwell JK, Gallagher LG, Kimberly R, et al. Cytokine gene polymorphism in human disease: on-line database. Genes Immun. 1999;1:3-19
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
22. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-αlpha, TNF-beta and TGF-beta1 gene polymorphisms. Transpl Immunol. 1999;7:127-128.
23. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
24. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94(7):3195-3199.
25. Patterson CE, Clauss MA. Signaling of prolonged activation: perspective on lung endothelial barrier function. Adv Mol Cell Biol. 2004;35:165-204.
26. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9:653-660.
27. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type a, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA. 1987l;84:5277-5281.
28. Guo DQ, Wu LW, Dunbar JD, et al. Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. JBiol Chem. 2000;275:11216-11221.
29. Montrucchio G, Lupia E, Battaglia E, et al. Tumor necrosis factor a-induced angiogenesis depends on insitu platelet-activating factor biosynthesis. J Exp Med. 1994;180:377-382.
30. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell DiffDev. 1990;32:319-327.
31. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinase: evolution, structure and function. Biochem Biophys Acta. 2000;1477:267-283.
32. Das A, McGuire PG, Eriqat C et al. Human diabetic neovascular membrane contains high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmology Vis Sci. 1999;40:809-813
33. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA micro-satellite marker of high IFN-gamma production. Hum Immunol. 2000;61:863-866.
34. Vallinoto AC, Grac ̧a ES, Araujo MS, et al. IFN-7 +874T/A polymorphism and cytokine plasma levels are associated with susceptibility to Mycobacterium tuberculosis infection and clinical manifestation of tuberculosis. Hum Immunol. 2010;71:692-696.
35. Spriewald BM, Witzke O, Wassmuth R, et al. Distinct tumour necrosis factor a, interferon 7, interleukin 10, and cytotoxic T-cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis. 2005;64:457-461.
36. Stanford MR, Vaughan RW, Kondeatis E, et al. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom? Br J Ophthalmol. 2005;89:1013-1016.
37. Sun B, Sun SH, Chan CC, Caspi RR. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res. 2000;70:493-502.
38. Kube D, Rieth H, Eskdale J, Kremsner PG, Gallagher G. Structural characterization of the distal 5' flanking region of the human interleukin-10 gene. Genes Immun. 2001;2:181-190.
39. Wilson JN, Rockett K, Jallow M, et al. Analysis of IL10 haplotypic association with severe malaria. Genes Immun. 2005;6:462-466.
40. Cordeiro CA, Moreira PR, Andrade MS, et al. Interleukin-10 gene polymorphism (-1082G/A) is associated with toxoplasmic retino-choroiditis. Invest Ophthalmol Vis Sci. 2008;49:1979-1982.
41. Atan D, Turner SJ, Kilmartin DJ, et al. Cytokine Gene Polymorphism in Sympathetic Ophthalmia. Invest Ophthalmol Vis Sci. 2005;46:4245-4250.
42. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2(1):25-31
43. Stearns ME, Rhim J, Wang M. Interleukin 10 (IL-10) inhibition of primary human prostate cell induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res. 1999;5:189-196.
44. Sfikakis PP, Grigoropoulos V, Markomichelakis N, Katsilambros N, Theodossiadis GP, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005;28:445-447.
45. Lipsky PE, Desiree MFM, van der Heijde. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
46. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 2004;50:1636-1641.
47. Ghosh S. Anti-TNF therapy in Crohn's disease Novartis. Found Symp. 2004;263:193-205.
48. Newton SM, Mackie SL, Martineau AR. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin Vaccine Immunol. 2008;15(3):506-512.
49. Chakravarty SD, Zhu G, Tsai MC. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun. 2008;76(3):916-926.